Global Metabolomics Services Market – Industry Trends and Forecast to 2028

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Exemple de rapport gratuitExemple de rapport gratuit Renseignez-vous avant d'acheterRenseignez-vous avant Acheter maintenantAcheter maintenant

Global Metabolomics Services Market – Industry Trends and Forecast to 2028

  • Healthcare IT
  • Upcoming Reports
  • Dec 2020
  • Global
  • 350 Pages
  • Nombre de tableaux : 220
  • Nombre de figures : 60

Contournez les défis liés aux tarifs grâce à un conseil agile en chaîne d'approvisionnement

L’analyse de l’écosystème de la chaîne d’approvisionnement fait désormais partie des rapports DBMR

Global Metabolomics Services Market, By Product and Service (Chromatography, Metabolomics Bioinformatics Services, Mass Spectrometry, Separation and Detection Services), Sample Type (Urine, Tumour, Cell Culture Media, Whole Blood, Food Ingredients, Plant, Others), Sample Source (Human, Animal, Others), End User (Medical Industry, Agriculture Industry, Food Processing Industry, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Metabolomics Services Market Market Analysis and Insights : Global Metabolomics Services Market

Metabolomics services market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 5,460.84 million by 2028 growing at a CAGR of 11.12% in the above-mentioned forecast period. The growing awareness amongst the physicians and patients regarding the benefits of metabolomics services which will generate immense opportunities that will led to the growth of the market.

The study and analysis of biochemical processes involving intermediates and by products of metabolic activities can be described as metabolomics. These products are known as metabolomes, which constitute a cluster of all the metabolites involved in an organism's various reactions, including signalling molecules, secondary metabolites, hormones, and metabolic intermediates.

Surging volume of patients suffering from neurological disorders, cancer, and cardiac diseases, increasing growth of the healthcare industry across the globe, increasing demand for personalized medicine, increase in the need for accurate disease diagnosis are some of the major as well as important factors which will likely to accelerate the growth of the metabolomics services market in the projected timeframe of 2021-2028. On the other hand, increasing number of technological advancement in the field of metabolomics, surging levels of investment from private as well as public sector on research and development activities along with increasing applications in the life science and biotechnology industry which will further contribute by generating immense opportunities that will led to the growth of the metabolomics services market in the above mentioned projected timeframe.

Increasing cost of instruments along with stringent regulations and policies which will likely to act as market restraints factor for the growth of the metabolomics services in the above mentioned projected timeframe. High cost of research and development along with issues with data examination and processing which will become the biggest and foremost challenge for the growth of the market.

This metabolomics services market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on metabolomics services market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Metabolomics Services Market Scope and Market Size

Metabolomics services market is segmented on the basis of product and service, sample type, sample source, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on product and service, the metabolomics services market is segmented into chromatography, metabolomics bioinformatics services, mass spectrometry, separation and detection services. Chromatography has been further segmented into paper chromatography, thin-layer chromatography, gas chromatography, and liquid chromatography. Separation and detection services have been further segmented into lipidomics, proteomics, targeted metabolite assays, and others.
  • On the basis of sample type, the metabolomics services market is segmented into urine, tumour, cell culture media, whole blood, food ingredients, plant, and others.
  • Based on sample source, the metabolomics services market is segmented into human, animal, and others.  
  • Metabolomics services market has also been segmented based on the end user into medical industry, agriculture industry, food processing industry, and others.

Metabolomics Services Market Country Level Analysis

Metabolomics services market is analysed and market size insights and trends are provided by country, product and services, sample type, sample source, and end user as referenced above.

The countries covered in the metabolomics services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the metabolomics services market due to the increasing occurrences of cancer, and cardiovascular diseases, while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2021 to 2028 due to the increasing development of healthcare infrastructure, surging levels of investment by various organizations on research and development activities along with growing levels of disposable income of the people in the region.

The country section of the metabolomics services market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Metabolomics services market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for metabolomics services market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the metabolomics services market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Metabolomics Services Market Share Analysis

Metabolomics services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to metabolomics services market.

The major players covered in the metabolomics services market report are WATERS; Agilent Technologies, Inc.; Bruker; TMIC; Thermo Fisher Scientific Inc.; biocrates life sciences ag; Creative Proteomics.; Metabolon, Inc.; Human Metabolome Technologies America Inc.; Shimadzu Corporation; SRI INTERNATIONAL; OWL; Cenix BioScience GmbH; West Coast Metabolomics Center; Stemina Biomarker Discovery, Inc.; Chenomx Inc.; Merck KGaA; Bio-Rad Laboratories, Inc.; PerkinElmer Inc.; Eurofins Scientific; among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL METABOLOMICS SERVICES MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL METABOLOMICS SERVICES MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL METABOLOMICS SERVICES MARKET : RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS

5.1 PATENT ANALYSIS

5.1.1 PATENT LANDSCAPE

5.1.2 USPTO NUMBER

5.1.3 PATENT EXPIRY

5.1.4 EPIO NUMBER

5.1.5 PATENT STRENGTH AND QUALITY

5.1.6 PATENT CLAIMS

5.1.7 PATENT CITATIONS

5.1.8 PATENT LITIGATION AND LICENSING

5.1.9 FILE OF PATENT

5.1.10 PATENT RECEIVED CONTRIES

5.1.11 TECHNOLOGY BACKGROUND

5.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

5.3 KEY PRICING STRATEGIES

5.4 INTERVIEWS WITH SPECIALIST

5.5 OTHER KOL SNAPSHOTS

6 MERGERS AND ACQUISITION

6.1 LICENSING

6.2 COMMERCIALIZATION AGREEMENTS

7 REGULATORY FRAMEWORK

7.1 REGULATORY APPROVAL PROCESS

7.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

7.3 REGULATORY APPROVAL PATHWAYS

7.4 LICENSING AND REGISTRATION

7.5 POST-MARKETING SURVEILLANCE

7.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

8 R & D ANALYSIS

8.1 COMPARATIVE ANALYSIS

8.2 TECHNOLOGY DEVELOPMENTAL LANDSCAPE

8.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

8.4 THERAPEUTIC ASSESSMENT

8.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

9 MARKET OVERVIEW

9.1 DRIVERS

9.2 RESTRAINTS

9.3 OPPORTUNITIES

9.4 CHALLENGES

10 GLOBAL METABOLOMICS SERVICES MARKET , SWOT AND DBMR ANALYSIS

11 GLOBAL METABOLOMICS SERVICES MARKET, BY PRODUCT AND SERVICE PROVIDED

11.1 OVERVIEW

11.2 SAMPLE ANALYTICS SERVICE

11.2.1 TARGETED METABOLOMICS SERVICES

11.2.1.1. FATTY ACIDS

11.2.1.2. AMINO ACIDS

11.2.1.3. BILE ACID

11.2.1.4. HORMONES

11.2.1.5. CARBOHYDRATES

11.2.1.6. LIPIDS

11.2.1.7. OTHERS

11.2.2 UNTARGETED METABOLOMICS SERVICES

11.2.3 UNKNOWN METABOLITE IDENTIFICATION

11.2.4 METABOLITE IDENTIFICATION AND PROFILING

11.2.5 PHARMACOKINETIC STUDIES

11.2.6 DRUG-DRUG INTERACTION STUDIES

11.2.7 TOXICOLOGY ASSESSMENT

11.2.8 XENOBIOTIC METABOLITES ANALYSIS SERVICE

11.2.9 METABOLIC FLUX ANALYSIS (MFA) SERVICE

11.2.10 ICP-MS IONOMICS PROFILING SERVICE

11.2.11 OTHERS

11.3 DATA ANALYTICS AND BIOINFORMATICS SERVICE

11.3.1 ON SITE ANALYSIS

11.3.2 CLOUD BASED

11.4 OTHERS

12 GLOBAL METABOLOMICS SERVICES MARKET, BY METABOLOME PROFILING TECHNIQUE USED

12.1.1 SEPERATION TOOLS

12.1.1.1. GAS CHROMATOGRAPHY (GC)

12.1.1.2. LIQUID CHROMATOGRAPHY (LC)

12.1.1.3. CAPILLARY ELECTROPHORESIS (CE)

12.1.1.4. OTHERS

12.1.2 DETECTION TOOLS

12.1.2.1. MASS SPECTROMETRY

12.1.2.1.1. FOURIER TRANSFORM ION CYCLOTRON RESONANCES (FT-ICR-MS),

12.1.2.1.2. ORBITRAP MS

12.1.2.1.3. MULTIPASS TOF-M

12.1.2.1.4. SINGLE QUADRUPOLE MASS SPECTROMETER

12.1.2.1.5. OTHERS

12.1.2.2. NMR SPECTROSCOPY

12.1.3 OTHERS

13 GLOBAL METABOLOMICS SERVICES MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 MEDICAL AND PHARMACUITICAL

13.2.1 DRUG DEVELOPMNET

13.2.1.1. DRUG DISCOVERY

13.2.1.2. PRECINICAL CLINICAL STUDIES

13.2.1.3. OTHERS

13.2.2 BIOMARKER DISCOVERY

13.2.3 PERSONALIZED MEDICINE

13.2.4 TOXOLOGY TESTING

13.2.5 OTHERS

13.3 AGRICULTURE

13.3.1 PLANT METABOLOMICS

13.3.2 PESTICIDE ANALYSIS

13.3.3 OTHERS

13.4 ENVIRONMNET

13.5 FOOD INDUSTRY

13.5.1 NUTRIGENOMICS

13.5.2 OTHERS

13.6 BIOMEDICAL INDUSTRY

13.6.1 FUNCTIONAL GENOMICS

13.6.2 OTERS

13.7 OTHERS

14 GLOBAL METABOLOMICS SERVICES MARKET, BY INDICATION

14.1 OVERVIEW

14.2 CANCER

14.3 CARDIOVASCULAR DISORDERS (CVD)

14.4 NEUROLOGICAL DISORDERS

14.5 INBORN ERRORS OF METABOLISM

14.6 INFECTIOUS DISEASE

14.7 OTHERS

15 GLOBAL METABOLOMICS SERVICES MARKET, BY SAMPLE TYPE

15.1 HUMAN

15.1.1 URINE

15.1.2 BLOOD

15.1.3 FECAL

15.1.4 TUMOR

15.1.5 OTHERS

15.2 MICROBIAL

15.3 CELL CULTURE

15.4 OTHERS

16 GLOBAL METABOLOMICS SERVICES MARKET, BY END USERS

16.1 OVERVIEW

16.2 HOSPITALS

16.3 CLINICS

16.4 ACADEMICS AND RESEARCH INSTITUTE

16.5 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

16.6 OTHERS

17 GLOBAL METABOLOMICS SERVICES MARKET , COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.5 MERGERS & ACQUISITIONS

17.6 NEW PRODUCT DEVELOPMENT & APPROVALS

17.7 EXPANSIONS

17.8 REGULATORY CHANGES

17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

18 GLOBAL METABOLOMICS SERVICES MARKET , BY REGION

Global METABOLOMICS SERVICES market , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

18.1 NORTH AMERICA

18.1.1 U.S.

18.1.2 CANADA

18.1.3 MEXICO

18.2 EUROPE

18.2.1 GERMANY

18.2.2 U.K.

18.2.3 ITALY

18.2.4 FRANCE

18.2.5 SPAIN

18.2.6 RUSSIA

18.2.7 SWITZERLAND

18.2.8 TURKEY

18.2.9 BELGIUM

18.2.10 NETHERLANDS

18.2.11 DENMARK

18.2.12 SWEDEN

18.2.13 POLAND

18.2.14 NORWAY

18.2.15 FINLAND

18.2.16 REST OF EUROPE

18.3 ASIA-PACIFIC

18.3.1 JAPAN

18.3.2 CHINA

18.3.3 SOUTH KOREA

18.3.4 INDIA

18.3.5 SINGAPORE

18.3.6 THAILAND

18.3.7 INDONESIA

18.3.8 MALAYSIA

18.3.9 PHILIPPINES

18.3.10 AUSTRALIA

18.3.11 NEW ZEALAND

18.3.12 VIETNAM

18.3.13 TAIWAN

18.3.14 REST OF ASIA-PACIFIC

18.4 SOUTH AMERICA

18.4.1 BRAZIL

18.4.2 ARGENTINA

18.4.3 REST OF SOUTH AMERICA

18.5 MIDDLE EAST AND AFRICA

18.5.1 SOUTH AFRICA

18.5.2 EGYPT

18.5.3 BAHRAIN

18.5.4 UNITED ARAB EMIRATES

18.5.5 KUWAIT

18.5.6 OMAN

18.5.7 QATAR

18.5.8 SAUDI ARABIA

18.5.9 REST OF MEA

18.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

19 GLOBAL METABOLOMICS SERVICES MARKET , COMPANY PROFILE

19.1 OVERVIEW

19.1.1 CREATIVE PROTEOMICS

19.1.1.1. COMPANY OVERVIEW

19.1.1.2. REVENUE ANALYSIS

19.1.1.3. GEOGRAPHIC PRESENCE

19.1.1.4. SERVICE PORTFOLIO

19.1.1.5. RECENT DEVELOPMENTS

19.1.2 AFEKTA TECHNOLOGIES

19.1.2.1. COMPANY OVERVIEW

19.1.2.2. REVENUE ANALYSIS

19.1.2.3. GEOGRAPHIC PRESENCE

19.1.2.4. PRODUCT PORTFOLIO

19.1.2.5. RECENT DEVELOPMENTS

19.1.3 BGI

19.1.3.1. COMPANY OVERVIEW

19.1.3.2. REVENUE ANALYSIS

19.1.3.3. GEOGRAPHIC PRESENCE

19.1.3.4. SERVICE PORTFOLIO

19.1.3.5. RECENT DEVELOPMENTS

19.1.4 ALBERT EINSTEIN COLLEGE OF MEDICINE

19.1.4.1. COMPANY OVERVIEW

19.1.4.2. REVENUE ANALYSIS

19.1.4.3. GEOGRAPHIC PRESENCE

19.1.4.4. SERVICE PORTFOLIO

19.1.4.5. RECENT DEVELOPMENTS

19.1.5 ANALYTICA LABORATORIES

19.1.5.1. COMPANY OVERVIEW

19.1.5.2. REVENUE ANALYSIS

19.1.5.3. GEOGRAPHIC PRESENCE

19.1.5.4. PRODUCT PORTFOLIO

19.1.5.5. RECENT DEVELOPMENTS

19.1.6 ANTI-DOPING LAB QATAR

19.1.6.1. COMPANY OVERVIEW

19.1.6.2. REVENUE ANALYSIS

19.1.6.3. GEOGRAPHIC PRESENCE

19.1.6.4. SERVICE PORTFOLIO

19.1.6.5. RECENT DEVELOPMENTS

19.1.7 THE METABOLOMICS INNOVATION CENTRE (TMIC)

19.1.7.1. COMPANY OVERVIEW

19.1.7.2. REVENUE ANALYSIS

19.1.7.3. GEOGRAPHIC PRESENCE

19.1.7.4. SERVICE PORTFOLIO

19.1.7.5. RECENT DEVELOPMENTS

19.1.8 SAPIENT

19.1.8.1. COMPANY OVERVIEW

19.1.8.2. REVENUE ANALYSIS

19.1.8.3. GEOGRAPHIC PRESENCE

19.1.8.4. SERVICE PORTFOLIO

19.1.8.5. RECENT DEVELOPMENTS

19.1.9 EVOTEC

19.1.9.1. COMPANY OVERVIEW

19.1.9.2. REVENUE ANALYSIS

19.1.9.3. GEOGRAPHIC PRESENCE

19.1.9.4. SERVICE PORTFOLIO

19.1.9.5. RECENT DEVELOPMENTS

19.1.10 HUMAN METABOLOME TECHNOLOGIES AMERICA, INC.

19.1.10.1. COMPANY OVERVIEW

19.1.10.2. REVENUE ANALYSIS

19.1.10.3. GEOGRAPHIC PRESENCE

19.1.10.4. SERVICE PORTFOLIO

19.1.10.5. RECENT DEVELOPMENTS

19.1.11 METWARE BIOTECHNOLOGY INC

19.1.11.1. COMPANY OVERVIEW

19.1.11.2. REVENUE ANALYSIS

19.1.11.3. GEOGRAPHIC PRESENCE

19.1.11.4. SERVICE PORTFOLIO

19.1.11.5. RECENT DEVELOPMENTS

19.1.12 METABOLON, INC.

19.1.12.1. COMPANY OVERVIEW

19.1.12.2. REVENUE ANALYSIS

19.1.12.3. GEOGRAPHIC PRESENCE

19.1.12.4. SERVICE PORTFOLIO

19.1.12.5. RECENT DEVELOPMENTS

19.1.13 VIENNA BIOCENTER

19.1.13.1. COMPANY OVERVIEW

19.1.13.2. REVENUE ANALYSIS

19.1.13.3. GEOGRAPHIC PRESENCE

19.1.13.4. SERVICE PORTFOLIO

19.1.13.5. RECENT DEVELOPMENTS

19.1.14 PANOMIX

19.1.14.1. COMPANY OVERVIEW

19.1.14.2. REVENUE ANALYSIS

19.1.14.3. GEOGRAPHIC PRESENCE

19.1.14.4. SERVICE PORTFOLIO

19.1.14.5. RECENT DEVELOPMENTS

19.1.15 BIOCRATES

19.1.15.1. COMPANY OVERVIEW

19.1.15.2. REVENUE ANALYSIS

19.1.15.3. GEOGRAPHIC PRESENCE

19.1.15.4. SERVICE PORTFOLIO

19.1.15.5. RECENT DEVELOPMENTS

19.1.16 SCIEX

19.1.16.1. COMPANY OVERVIEW

19.1.16.2. REVENUE ANALYSIS

19.1.16.3. GEOGRAPHIC PRESENCE

19.1.16.4. SERVICE PORTFOLIO

19.1.16.5. RECENT DEVELOPMENTS

19.1.17 EMERY PHARMA

19.1.17.1. COMPANY OVERVIEW

19.1.17.2. REVENUE ANALYSIS

19.1.17.3. GEOGRAPHIC PRESENCE

19.1.17.4. SERVICE PORTFOLIO

19.1.17.5. RECENT DEVELOPMENTS

19.1.18 CHARLES RIVER LABORATORIES

19.1.18.1. COMPANY OVERVIEW

19.1.18.2. REVENUE ANALYSIS

19.1.18.3. GEOGRAPHIC PRESENCE

19.1.18.4. SERVICE PORTFOLIO

19.1.18.5. RECENT DEVELOPMENTS

19.1.19 COSMOSID

19.1.19.1. COMPANY OVERVIEW

19.1.19.2. REVENUE ANALYSIS

19.1.19.3. GEOGRAPHIC PRESENCE

19.1.19.4. SERVICE PORTFOLIO

19.1.19.5. RECENT DEVELOPMENTS

19.1.20 THE PHILIPPINE GENOME CENTER

19.1.20.1. COMPANY OVERVIEW

19.1.20.2. REVENUE ANALYSIS

19.1.20.3. GEOGRAPHIC PRESENCE

19.1.20.4. SERVICE PORTFOLIO

19.1.20.5. RECENT DEVELOPMENTS

19.1.21 GENETIKA SCIENCE

19.1.21.1. COMPANY OVERVIEW

19.1.21.2. REVENUE ANALYSIS

19.1.21.3. GEOGRAPHIC PRESENCE

19.1.21.4. SERVICE PORTFOLIO

19.1.21.5. RECENT DEVELOPMENTS

19.1.22 OWL METABOLOMICS

19.1.22.1. COMPANY OVERVIEW

19.1.22.2. REVENUE ANALYSIS

19.1.22.3. GEOGRAPHIC PRESENCE

19.1.22.4. SERVICE PORTFOLIO

19.1.22.5. RECENT DEVELOPMENTS

19.1.23 WEST COAST METABOLOMICS CENTER

19.1.23.1. COMPANY OVERVIEW

19.1.23.2. REVENUE ANALYSIS

19.1.23.3. GEOGRAPHIC PRESENCE

19.1.23.4. SERVICE PORTFOLIO

19.1.23.5. RECENT DEVELOPMENTS

19.1.24 STEMINA BIOMARKER DISCOVERY, INC.

19.1.24.1. COMPANY OVERVIEW

19.1.24.2. REVENUE ANALYSIS

19.1.24.3. GEOGRAPHIC PRESENCE

19.1.24.4. SERVICE PORTFOLIO

19.1.24.5. RECENT DEVELOPMENTS

19.1.25 CHENOMX INC.

19.1.25.1. COMPANY OVERVIEW

19.1.25.2. REVENUE ANALYSIS

19.1.25.3. GEOGRAPHIC PRESENCE

19.1.25.4. SERVICE PORTFOLIO

19.1.25.5. RECENT DEVELOPMENTS

19.1.26 METAWARE BIO

19.1.26.1. COMPANY OVERVIEW

19.1.26.2. REVENUE ANALYSIS

19.1.26.3. GEOGRAPHIC PRESENCE

19.1.26.4. SERVICE PORTFOLIO

19.1.26.5. RECENT DEVELOPMENTS

19.1.27 LIPOTYPE

19.1.27.1. COMPANY OVERVIEW

19.1.27.2. REVENUE ANALYSIS

19.1.27.3. GEOGRAPHIC PRESENCE

19.1.27.4. SERVICE PORTFOLIO

19.1.27.5. RECENT DEVELOPMENTS

19.1.28 CAYMANCHEM

19.1.28.1. COMPANY OVERVIEW

19.1.28.2. REVENUE ANALYSIS

19.1.28.3. GEOGRAPHIC PRESENCE

19.1.28.4. SERVICE PORTFOLIO

19.1.28.5. RECENT DEVELOPMENTS

19.1.29 SEGAL CANCER PROTEOMICS CENTRE

19.1.29.1. COMPANY OVERVIEW

19.1.29.2. REVENUE ANALYSIS

19.1.29.3. GEOGRAPHIC PRESENCE

19.1.29.4. SERVICE PORTFOLIO

19.1.29.5. RECENT DEVELOPMENTS

19.1.30 SWEDISH METABOLOMICS CENTRE

19.1.30.1. COMPANY OVERVIEW

19.1.30.2. REVENUE ANALYSIS

19.1.30.3. GEOGRAPHIC PRESENCE

19.1.30.4. SERVICE PORTFOLIO

19.1.30.5. RECENT DEVELOPMENTS

20 RELATED REPORTS

21 CONCLUSION

22 QUESTIONNAIRE

23 ABOUT DATA BRIDGE MARKET RESEARCH

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

Le marché est segmenté en fonction de , By Product and Service (Chromatography, Metabolomics Bioinformatics Services, Mass Spectrometry, Separation and Detection Services), Sample Type (Urine, Tumour, Cell Culture Media, Whole Blood, Food Ingredients, Plant, Others), Sample Source (Human, Animal, Others), End User (Medical Industry, Agriculture Industry, Food Processing Industry, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028 .
La taille du Global Metabolomics Services Market était estimée à 0.00 USD Million USD en 2021.
Le Global Metabolomics Services Market devrait croître à un TCAC de 0% sur la période de prévision de 2022 à 2028.
Les principaux acteurs du marché sont ,WATERS, Agilent TechnologiesInc., Bruker, TMIC, Thermo Fisher Scientific Inc., biocrates life sciences ag, Creative Proteomics., MetabolonInc., Human Metabolome Technologies America Inc., Shimadzu Corporation, SRI INTERNATIONAL, OWL, Cenix BioScience GmbH, West Coast Metabolomics Center, Stemina Biomarker DiscoveryInc., Chenomx Inc., Merck KGaA, Bio-Rad LaboratoriesInc., PerkinElmer Inc., Eurofins Scientific, .
Testimonial